Amyris and BASF Reach Agreement for Strain Engineering Collaboration
EMERYVILLE, Calif., April 3, 2014 (GLOBE NEWSWIRE) -- Amyris, Inc.
(Nasdaq:AMRS) announced that it is entering into a collaborative research and
development agreement with BASF SE (XETRA:BAS). Under the agreement, Amyris
will use its strain engineering technology to develop a microorganism capable
of producing a target molecule identified by BASF.
"Through this new collaboration, Amyris will seek to develop strains capable
of producing a relevant target molecule for BASF, which could help performance
and competitiveness with the traditional sources for that molecule. Amyris's
synthetic biology and strain engineering technology platform and BASF's
capabilities and superior market leadership in the chemicals industry are
complementary, and, I believe, our two companies can build on this initial
effort to lead the way to innovative renewable chemicals produced through
industrial biotechnology," said John Melo, President & CEO of Amyris.
Based on success of the initial development program, the companies expect to
collaborate further on a strain development program and consider other joint
research and development opportunities. The companies have agreed not to
disclose any details of the agreement.
Amyris is an integrated renewable products company focused on providing
sustainable alternatives to a broad range of petroleum-sourced products.
Amyris uses its industrial synthetic biology platform to convert plant sugars
into a variety of molecules -- flexible building blocks that can be used in a
wide range of products. Amyris's initial portfolio of commercial products is
based on Biofene®, Amyris's brand of renewable farnesene, a long-chain
hydrocarbon. Amyris is commercializing these products both as No Compromise®
renewable ingredients in cosmetics, flavors and fragrances, polymers,
lubricants and consumer products, and also as No Compromise renewable diesel
and jet fuel. Amyris Brasil Ltda., a subsidiary of Amyris, oversees the
establishment and commercialization of Amyris's production in Brazil.
Amyris Forward-Looking Statements
This release contains forward-looking statements, and any statements other
than statements of historical facts could be deemed to be forward-looking
statements. These forward-looking statements include, among other things,
statements regarding future events (such as the plans for a development
program and the results and benefits of the program) that involve risks and
uncertainties. These statements are based on management's current expectations
and actual results and future events may differ materially due to risks and
uncertainties, including those associated with any delays or failures in
development, production and commercialization of products, liquidity and
ability to fund capital expenditures, Amyris's reliance on third parties to
achieve its goals, and other risks detailed in the "Risk Factors" section of
Amyris's quarterly report on Form 10-K filed on April 2, 2014. Amyris
disclaims any obligation to update information contained in these
forward-looking statements whether as a result of new information, future
events, or otherwise.
Amyris, the Amyris logo, Biofene and No Compromise are trademarks or
registered trademarks of Amyris, Inc.
CONTACT: Amyris, Inc.
Press spacebar to pause and continue. Press esc to stop.